Fundraising Fox
/Companies
Sign in

LIPAC Oncology

Pomona, US · Founded 2016 · Delaware LLC

Find your way into LIPAC Oncology

Sign up to see every warm intro you have to LIPAC Oncology

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the LIPAC Oncology team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

LIPAC Oncology is a pharmaceutical company developing chemotherapy treatments based on LiPax, a neoliposomal platform for local, targeted delivery of paclitaxel to treat intracavitary carcinomas. Its lead program targets non-muscle invasive bladder cancer, with additional indications in thoracic, upper tract urothelial, peritoneal, and ovarian cancers.

BiotechHealthtechMedical Devices

Founders & leadership

LIPAC Oncology was founded in 2016 by Ramachandran "TR" Thirucote and Michael Oefelein.

R"Ramachandran "TR" Thirucote
Ramachandran "TR" ThirucoteFounding Chairman & Chief Executive OfficerDr. Ramachandran Thirucote is a pharmaceutical scientist with experience in drug formulation and development across multiple dosage forms. He previously led product development at Agouron Pharmaceuticals, directed early-stage pharmaceutical development efforts at SRI International, and served as Principal Investigator on NIH contracts with NIAID and NCI; he is founding chairman and CEO of LIPAC Oncology.
MOMichael Oefelein
Michael OefeleinCo-founder & Chief Medical OfficerMichael Oefelein is a board-certified physician and Fellow of the American College of Surgeons with over 15 years of experience in pharmaceutical and device development across urology, oncology, dermatology, and other specialties. He has authored nearly 100 peer-reviewed publications and has led the design and execution of clinical trials, including registration, safety, and regulatory studies for multiple genitourinary and systemic agents.
WA
Willem A RobbertsNamed on SEC filing
TR
Thirucote RamachandranNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$372.5K disclosed across 1 round · 2020

▶$372.5KraisedJul 2020 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Willem A RobbertsExecutive Officer, Director
  • Thirucote RamachandranExecutive Officer, Director
Offering amount
$5M
Amount sold
$372.5K
First sale
Jan 2020
Incorporated
Limited Liability Company, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

CancerresearchukCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.

Companies working in the same space as LIPAC Oncology.

In the news

LIPAC Oncology to Present at Upcoming Investor Conferencesprnewswire.com · Sep 2021LIPAC Oncology Announces Presentation of Data from Phase 1/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer - BioSpacebiospace.com · May 2020

Frequently asked questions

What does LIPAC Oncology do?
LIPAC Oncology is a pharmaceutical company developing chemotherapy treatments based on LiPax, a neoliposomal platform for local, targeted delivery of paclitaxel to treat intracavitary carcinomas. Its lead program targets non-muscle invasive bladder cancer, with additional indications in thoracic, upper tract urothelial, peritoneal, and ovarian cancers.
Who founded LIPAC Oncology?
LIPAC Oncology was founded by Ramachandran "TR" Thirucote, Michael Oefelein in 2016.
How much funding has LIPAC Oncology raised?
LIPAC Oncology has disclosed $372.5K raised across 1 round.
Where is LIPAC Oncology headquartered?
LIPAC Oncology is headquartered in Pomona, US.